ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ensysce Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.50−0.02 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ensysce Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MPAR [Member] | $4.50M | $4.71M | $5.07M | $4.49M | $5.78M | $3.09M | – | – | – | $1.29M | $2.33M | $2.42M | 100.0% | -22.1% |
| TAAP/OUD [Member] | – | – | – | – | – | $2.12M | $2.38M | $1.06M | $934.65K | $937.28K | $814.34K | $571.97K | – | – |
By region
From the segment and revenue-disaggregation notes of Ensysce Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.